BAI1 Antibody

What is BAI1 and what are its primary biological functions?

BAI1 (Brain Angiogenesis Inhibitor 1) is a 170 kDa 7-transmembrane domain G protein-coupled receptor (GPCR) with a large N-terminal extracellular region containing an RGD motif, five thrombospondin type I repeats, and a juxtamembrane GPS (GPCR proteolytic cleavage site) . This receptor serves multiple biological functions, primarily:

• Acting as a phosphatidylserine receptor that enhances the engulfment of apoptotic cells

• Functioning as a pattern recognition receptor for Gram-negative bacteria, mediating their binding and engulfment

• Stimulating production of reactive oxygen species by macrophages in response to Gram-negative bacteria

• Serving as a potent inhibitor of angiogenesis, particularly in brain tissue, potentially functioning as a mediator of p53/TP53 signaling in glioblastoma suppression

• Promoting myoblast fusion and regulating synaptic plasticity by inhibiting MDM2-mediated ubiquitination and degradation of DLG4/PSD95

While BAI1 is preferentially expressed in brain neurons, it is also found in astrocytes, macrophages, and tissues including pancreas, stomach, and colon .

What applications are BAI1 antibodies suitable for in research settings?

BAI1 antibodies have been validated for multiple research applications, each providing different insights into BAI1 expression and function:

• Western Blotting (WB): For detecting and quantifying BAI1 protein in cell or tissue lysates

• Immunohistochemistry with paraffin-embedded tissues (IHC-P): For visualizing BAI1 localization in fixed tissue sections

• Immunohistochemistry with frozen tissues (IHC-Fr): For detecting BAI1 in frozen tissue sections, which may preserve certain epitopes better than paraffin embedding

• Flow Cytometry: For detecting BAI1 in cell populations and sorting cells based on BAI1 expression levels

• Immunocytochemistry (ICC): For examining subcellular localization of BAI1 in cultured cells

Researchers should verify the validation status of specific antibodies for their intended applications and species of interest, as performance can vary significantly between different antibody clones and experimental conditions .

What species reactivity can be expected with commercially available BAI1 antibodies?

Most characterized BAI1 antibodies demonstrate reactivity with human and mouse samples . This cross-species reactivity is supported by the high sequence homology between species - within the extracellular domain up to the GPS (amino acids 31-879), mature human BAI1 shares 94% amino acid sequence identity with mouse and rat BAI1 .

When selecting an antibody for a specific species, researchers should consider:

• Validated species reactivity as reported by manufacturers

• The degree of conservation in the antigenic region between target species

• Whether the antibody has been tested in the specific application of interest for that species

For example, Abcam's rabbit polyclonal BAI1 antibody (ab135907) has been validated for both mouse and human samples across multiple applications . When working with less common species, researchers may need to perform preliminary validation experiments to confirm cross-reactivity.

How can BAI1 antibodies be used to study the recognition and phagocytosis of Gram-negative bacteria?

BAI1 functions as a pattern recognition receptor that specifically recognizes Gram-negative bacteria through an interaction between its thrombospondin type I repeats (TSRs) and bacterial lipopolysaccharide (LPS) . To investigate this function, researchers can employ BAI1 antibodies in several experimental approaches:

Bacterial Binding Assays:

• Use flow cytometry with FITC-labeled bacteria to quantify binding to cells expressing BAI1, with BAI1 antibodies as blocking agents to confirm specificity

• Preincubate bacteria with recombinant soluble BAI1 ectodomain to demonstrate direct binding

• Employ BAI1 antibodies to immunoprecipitate bacteria-BAI1 complexes to confirm physical interaction

Phagocytosis Studies:

• Utilize gentamicin protection assays in conjunction with BAI1 overexpression or knockdown to quantify bacterial internalization

• Compare phagocytosis of different bacterial species (Gram-negative vs. Gram-positive) to demonstrate specificity - BAI1 has been shown to enhance binding of Gram-negative species like Salmonella typhimurium, Escherichia coli, and Campylobacter jejuni, but not Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and group A Streptococcus

• Use immunofluorescence microscopy with BAI1 antibodies to visualize colocalization of BAI1 with internalized bacteria

These approaches can be combined with inhibitors of downstream signaling components to delineate the BAI1-mediated phagocytic pathway, which involves ELMO1/Dock/Rac1 signaling .

What mechanisms underlie BAI1's role in angiogenesis inhibition, and how can this be studied?

BAI1 exhibits potent anti-angiogenic properties through multiple mechanisms that can be investigated using BAI1 antibodies:

Mechanisms of Angiogenesis Inhibition:

• Proteolytic cleavage of BAI1 releases a 120 kDa fragment called Vasculostatin, which corresponds to nearly the entire N-terminal extracellular domain

• BAI1 fragments interact with Integrin alpha V beta 5 or CD36 on microvascular endothelial cells to inhibit cell proliferation and migration

• Overexpression of BAI1 in tumor cells inhibits tumor-associated neovascularization

Experimental Approaches:

• Use BAI1 antibodies to detect cleaved fragments (Vasculostatin) in cell culture supernatants or tissue samples via Western blotting

• Employ immunohistochemistry with BAI1 antibodies to correlate BAI1 expression with microvessel density in tumor samples

• Develop co-culture systems with endothelial cells and BAI1-expressing cells, using antibodies to neutralize BAI1 function or detect its expression

• Perform in vivo angiogenesis assays (e.g., Matrigel plug assay) with BAI1-overexpressing cells and use antibodies to confirm expression

Studies have shown that BAI1 expression is inversely correlated with tumor vascularity in colorectal and pulmonary carcinomas, suggesting its potential role as a biomarker for tumor progression . Additionally, BAI1 is frequently downregulated in several cancer types, including glioblastoma and carcinomas of the pancreas, colon, and stomach .

How can researchers optimize the validation of BAI1 antibody specificity?

Validating antibody specificity is crucial for ensuring reliable experimental results. For BAI1 antibodies, several complementary approaches can be employed:

Genetic Validation:

• Compare antibody reactivity in wild-type cells versus BAI1 knockdown (siRNA or CRISPR) or knockout models

• Overexpress BAI1 in cell lines with low endogenous expression and confirm increased signal

Biochemical Validation:

• Perform peptide competition assays using the immunizing peptide (e.g., synthetic peptide within Human ADGRB1 aa 650-750 for certain antibodies)

• Test reactivity against recombinant BAI1 protein fragments

• Compare signal across multiple BAI1 antibodies targeting different epitopes

Application-Specific Validation:

• For immunohistochemistry: Compare staining patterns in tissues known to express BAI1 (brain neurons) versus tissues with low expression

• For flow cytometry: Use appropriate positive and negative cell lines (e.g., U2OS human osteosarcoma cell line as positive and MCF-7 human breast cancer cell line as negative control)

• For Western blotting: Verify that the detected band matches the expected molecular weight (170 kDa for full-length BAI1 or 120 kDa for Vasculostatin)

Cross-Platform Validation:
Compare BAI1 detection across multiple techniques (e.g., Western blot, immunofluorescence, and flow cytometry) to ensure concordant results .

What controls should be included when using BAI1 antibodies in experimental settings?

Proper controls are essential for interpreting results obtained with BAI1 antibodies. Researchers should consider including:

Negative Controls:

• Isotype control antibodies to account for non-specific binding (e.g., Mouse IgG control for mouse monoclonal anti-BAI1)

• Cell lines or tissues with low/no BAI1 expression (e.g., MCF-7 human breast cancer cell line has been used as a negative control)

• BAI1 knockdown or knockout samples to confirm antibody specificity

• Secondary antibody-only controls to assess background staining

Positive Controls:

• Cell lines with known BAI1 expression (e.g., U2OS human osteosarcoma cells)

• Tissues with established BAI1 expression (brain tissue, particularly neurons)

• Recombinant BAI1 protein or cells transfected with BAI1 expression constructs

Functional Controls:

• For phagocytosis assays: Compare Gram-negative bacteria (should bind to BAI1) with Gram-positive bacteria (should not bind)

• For angiogenesis studies: Compare the effects of BAI1 overexpression versus knockdown on endothelial cell proliferation or migration

• For bacterial recognition studies: Use an LPS-deficient bacterial strain as a negative control

These controls help ensure that observed effects are specifically due to BAI1 and not experimental artifacts or non-specific antibody binding.

What methodological approaches can be used to study BAI1-mediated signaling pathways?

BAI1 engages multiple downstream signaling pathways that can be studied using various techniques in conjunction with BAI1 antibodies:

ELMO1/Dock/Rac1 Pathway:

• Co-immunoprecipitation assays using BAI1 antibodies to pull down interacting proteins (ELMO1, Dock180)

• Rac1 activation assays (G-LISA or pull-down with PAK-PBD) following BAI1 stimulation or manipulation

• Inhibition of the BAI1/ELMO1 interaction using peptide inhibitors or mutation of the interaction domains to assess effects on downstream signaling and bacterial uptake

Inflammatory Signaling:

• Quantify proinflammatory cytokine production (e.g., TNF-α) in response to bacterial challenge in cells with normal or altered BAI1 expression

• Use flow cytometry or immunoblotting to detect activation of MAPKs and NF-κB pathway components downstream of BAI1 activation

Rho GTPase Pathway:

• Assess BAI1-mediated activation of the Rho pathway in G-protein-dependent manner using FRET-based biosensors or traditional pull-down assays

• Examine cytoskeletal rearrangements associated with BAI1 activation using fluorescence microscopy

Experimental Approaches:

• Use BAI1 antibodies to immunoprecipitate receptor complexes before and after stimulation with ligands (apoptotic cells, bacteria)

• Employ phospho-specific antibodies to detect activation of downstream signaling components

• Utilize pharmacological inhibitors of specific pathway components to dissect the signaling cascade

Studies have shown that inhibition of ELMO1 or Rac function significantly impairs the proinflammatory response to infection, indicating that BAI1-mediated Rac activation is necessary not only for engulfment of bound bacteria but also for efficient downstream inflammatory responses .

What are the optimal conditions for using BAI1 antibodies in different applications?

Optimal conditions for BAI1 antibody use vary by application and specific antibody clone. Based on the search results, here are some guidelines:

Western Blotting:

• Dilution: 1/500 has been reported for some antibodies

• Sample preparation: Ensure complete protein denaturation to expose BAI1 epitopes

• Controls: Include positive controls such as brain tissue lysates or BAI1-overexpressing cells

Immunohistochemistry:

• Antigen retrieval: May be necessary for paraffin-embedded tissues to expose epitopes

• Dilution: Optimize based on specific antibody and tissue type

• Counterstaining: DAPI for nuclear visualization can help with localization assessment

Flow Cytometry:

• Cell preparation: Ensure cells are properly fixed and permeabilized if the antibody targets an intracellular epitope

• Controls: Use appropriate gating controls and isotype antibodies

• Secondary antibody: APC-conjugated or other fluorophore-conjugated secondary antibodies can be used

Immunocytochemistry:

• Concentration: 8 μg/mL has been reported for some antibodies

• Incubation time: 3 hours at room temperature has been used successfully

• Visualization: Secondary antibodies such as NorthernLights™ 557-conjugated Anti-Mouse IgG have been employed

For all applications, researchers should:

• Perform antibody titration experiments to determine optimal concentration

• Include appropriate positive and negative controls

• Follow manufacturer recommendations as starting points

How can researchers address potential cross-reactivity or non-specific binding with BAI1 antibodies?

Cross-reactivity and non-specific binding can complicate the interpretation of results when using BAI1 antibodies. Several strategies can mitigate these issues:

Reducing Non-specific Binding:

• Optimize blocking conditions using appropriate blocking agents (BSA, normal serum, or commercial blocking solutions)

• Titrate primary and secondary antibody concentrations to find the optimal signal-to-noise ratio

• Include detergents (like Tween-20) in washing buffers to reduce hydrophobic interactions

• Pre-adsorb antibodies with tissues or cell lysates from species used in experiments

Addressing Cross-reactivity:

• Use monoclonal antibodies when high specificity is required, as they target a single epitope

• Verify antibody specificity using BAI1 knockout or knockdown models

• Perform peptide competition assays with the immunizing peptide

• Compare staining patterns across different antibodies targeting distinct BAI1 epitopes

Validation Approaches:

• Compare staining patterns in cells known to express BAI1 (U2OS) versus those with little/no expression (MCF-7)

• Use orthogonal methods to confirm BAI1 expression (e.g., mRNA analysis via qPCR)

• For flow cytometry, use quadrant markers based on control antibody staining to distinguish positive from negative populations

By implementing these strategies, researchers can increase confidence in the specificity of their BAI1 antibody and the reliability of their experimental results.

How can BAI1 antibodies be used to investigate the receptor's role in discriminating between different types of bacteria?

BAI1 shows selectivity for Gram-negative bacteria over Gram-positive bacteria, making it an interesting model for studying pathogen recognition specificity . BAI1 antibodies can be instrumental in investigating this discriminatory function:

Experimental Approaches:

• Flow cytometry assays with FITC-labeled bacteria of different species to quantify binding in the presence or absence of BAI1 antibodies

• Competition assays using purified bacterial components (LPS, peptidoglycan) to determine specific molecular recognition determinants

• Domain-specific BAI1 antibodies to map which regions of BAI1 are critical for bacterial recognition

• Mutation studies targeting specific residues in the TSR domains combined with antibody detection to correlate structure with binding function

Research has demonstrated that BAI1 preferentially recognizes Gram-negative bacteria (S. typhimurium, E. coli, and C. jejuni) through an interaction between its thrombospondin repeats (TSRs) and bacterial surface lipopolysaccharide (LPS) . This specificity can be leveraged to study pattern recognition receptor evolution and host-pathogen interactions.

What techniques can be used to investigate the biophysical properties of BAI1 antibody-antigen interactions?

Understanding the biophysical properties of BAI1 antibody-antigen interactions can provide insights into binding mechanisms and help design better experimental approaches:

Surface Plasmon Resonance (SPR):

• Measure real-time binding kinetics (kon and koff rates) between BAI1 antibodies and purified BAI1 protein

• Determine binding affinity (KD) under various conditions

• Assess the effects of mutations or post-translational modifications on binding

Isothermal Titration Calorimetry (ITC):

• Characterize thermodynamic parameters of antibody-BAI1 interactions

• Determine binding stoichiometry and entropy/enthalpy contributions

Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

• Map epitopes by identifying regions of BAI1 protected from exchange when bound to antibodies

• Understand conformational changes induced by antibody binding

Computational Modeling:

• Predict antibody-antigen interactions using machine learning approaches similar to those described for other antibodies

• Model different binding modes associated with specific ligands

• Design antibodies with customized specificity profiles

These techniques can help researchers better understand the molecular basis of BAI1 recognition by different antibodies and potentially develop antibodies with improved specificity or affinity.